Sensitivity of quantitative metrics derived from DCE MRI and a pharmacokinetic model to image quality and acquisition parameters.

RATIONALE AND OBJECTIVES This study aims to investigate the sensitivity of quantitative metrics derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging and a pharmacokinetic (PK) model to image quality and acquisition parameters. MATERIALS AND METHODS A computer-synthesized DCE model that consisted of a large range of values of K(trans) (transfer constant of a paramagnetic contrast agent from blood to tissue), v(p) (fractional plasma volume), and k(ep) (back flux rate) was created to test the reliability of quantitative metrics derived from a standard PK model. Effects of the contrast-to-noise ratio (CNR), total acquisition time, and sampling interval on the stability and bias of the derived metrics were investigated. RESULTS The instability and bias of the estimated K(trans), v(p), and k(ep) values increased with sampling interval and decreased with increasing CNR. Total acquisition times had limited influence on the estimations of K(trans) and v(p) values, but increasing the total acquisition time improved the stability of the estimation of k(ep) values. However, for small k(ep) values, the stability was still poor even with a total acquisition time of 8 minutes. Also, the stability and bias of the estimated values of K(trans), v(p), and k(ep) are interrelated. CONCLUSIONS Our synthesized DCE model represents perfectly reproduced data except for the presence of Gaussian-distributed random noise. Our analysis suggests minimum changes that may be considered potentially significant in longitudinal therapy assessment studies. Our data are complementary to experimental data from human subjects and phantoms, and provide guidance for the design of image acquisition strategies.

[1]  Lian Li,et al.  Patlak plots of Gd‐DTPA MRI data yield blood–brain transfer constants concordant with those of 14C‐sucrose in areas of blood–brain opening , 2003, Magnetic resonance in medicine.

[2]  Avraham Eisbruch,et al.  Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. , 2008, International journal of radiation oncology, biology, physics.

[3]  Hai-Ling Margaret Cheng,et al.  Investigation and optimization of parameter accuracy in dynamic contrast‐enhanced MRI , 2008, Journal of magnetic resonance imaging : JMRI.

[4]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[5]  A. Padhani,et al.  Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Aytekin Oto,et al.  Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced–MRI analysis , 2009, Magnetic resonance in medicine.

[7]  H. Buchtel,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction , 2009, Clinical Cancer Research.

[8]  A. Padhani,et al.  Reproducibility of quantitative dynamic MRI of normal human tissues , 2002, NMR in biomedicine.

[9]  Laurent Hermoye,et al.  Inflow correction of hepatic perfusion measurements using T1‐weighted, fast gradient‐echo, contrast‐enhanced MRI , 2004, Magnetic resonance in medicine.

[10]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[11]  Mohammad Haris,et al.  Improved bolus arrival time and arterial input function estimation for tracer kinetic analysis in DCE‐MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[12]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Gadian,et al.  Delay and dispersion effects in dynamic susceptibility contrast MRI: Simulations using singular value decomposition , 2000, Magnetic resonance in medicine.

[14]  B K Rutt,et al.  Temporal sampling requirements for the tracer kinetics modeling of breast disease. , 1998, Magnetic resonance imaging.

[15]  Yue Cao,et al.  WE‐D‐T‐6C‐03: Development of Image Software Tools for Radiation Therapy Assessment , 2005 .

[16]  Natal A W van Riel,et al.  On the identifiability of pharmacokinetic parameters in dynamic contrast‐enhanced imaging , 2007, Magnetic resonance in medicine.

[17]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  A. Jackson,et al.  Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. , 2003, The British journal of radiology.